A Phase 2 interventional study of Sodium Zirconium Cyclosilicate and Placebo in Heart Failure, sponsored by AstraZeneca. Terminated at 76 sites in 9 countries. Open to participants aged 18 Years to 150 Years. Per ClinicalTrials.gov, last updated 2021-06-15.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Heart Failure by AstraZeneca — 5 open to participants now, 8 under way, 3 of them phase 3. Heart Failure · AstraZeneca.
Among the 64 studies in Heart Failure by AstraZeneca, this one is the 19th largest by enrollment of the 39 interventional ones that give a count, is one of 8 that started in 2018, is one of 8 in phase 2, and was the 21st registered.
6,339 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →5 of the 64 studies in Heart Failure by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Australia and 29 more countries
Ages 18+
AstraZeneca · Sites in United States, Germany, Portugal and 2 more countries
Ages 18+
AstraZeneca · Sites in United States, Denmark, France and 1 more country
Ages 12–130
AstraZeneca · Sites in United States, Argentina, Australia and 32 more countries
Ages 40+
AstraZeneca · Sites in Brazil, Chile, Costa Rica and 17 more countries
Ages 18+
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years to 150 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 9 · Phase 3 16 · Phase 4 2
First in 1999; this study’s year is marked. 8 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 182 is above the median of 76 across 4,052 interventional studies indexed under Heart Failure.
Median enrollment 160 across the 39 interventional studies, 621 across the 25 observational. Of the 54 that completed or were terminated, 14 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
4 of the studies in Heart Failure by AstraZeneca that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT06336330AstraZenecaReal-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in Germany | 2026-12-31 |
| NCT07690436AstraZenecaRetinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM | 2027-06-18 |
| NCT06675552AstraZenecaNon-interventional Study on Guideline Directed Medical Therapy for Patients With Heart Failure (HF) in Germany | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 64 studies in Heart Failure by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an international, multicentre, parallel-group, randomised, double-blind, placebo controlled, phase II study to evaluate the benefits and risks of using sodium zirconium cyclosilicate (ZS) to initiate and intensify renin angiotensin aldosterone system inhibitor (RAASi) therapy in heart failure patients.
Patients with chronic heart failure (NYHA II-IV) and serum potassium > 5.0 mmol/L or at high risk of developing hyperkalaemia will be enrolled. Patients signing informed consent will be screened for up to 14 days. Patients meeting the inclusion criteria, but not the exclusion criteria, are then randomized in a 1:1 ratio to receive ZS or placebo for 3 months while titrating RAASi therapies. Approximately 280 patients will be randomized in the study. Study treatment in this study refers to ZS or placebo, while RAASi therapies are considered background therapy and will not be provided by the study sponsor. Patients will participate in the study for approximately 16 to 18 weeks in total, depending on the duration of the screening period. A Safety Review Committee will be established to review emerging safety data
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Individuals with mild hyperkalaemia or at risk of developing hyperkalaemia during the study, as defined by meeting all of the criteria in any one of the 3 categories listed below:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Powder for oral suspension
Drug: Sodium Zirconium Cyclosilicate
Powder for oral suspension
Drug: Placebo
Oral use for approximately 3 months
Also known as: ZS; Lokelma
Oral use for approximately 3 months
Also known as: PBO
Percentage of Patients Receiving Different Categories of RAASi Treatments at Month 3
RAASi treatment categories: * No, or less than target dose, angiotensin converting enzyme inhibitors (ACEi)/ angiotensin receptor blockers (ARB)/ angiotensin receptor/ neprolysin inhibitors (ARNI) and no mineralocorticoid receptor antagonist (MRA); * ACEi/ARB/ARNI at target dose and no MRA; * MRA at less than target dose; * MRA at target dose. Missing values at 3 months were imputed using a multiple imputation approach with 10000 imputations. The imputation model included RAASi category at 3 months as the outcome variable and the following covariates: RAASi category, local lab-K, eGFR and systolic blood pressure measured at the last visit before the 3 months (starting with the randomisation visit) when all the covariates' data were available.
Time frame: At the end of the treatment visit (Month 3)
Number of Patients Who Experienced Adverse Events (AEs) During the Study
An AE is the development of any untoward medical occurrence in a patient or clinical study patient administered an investigational product (IP) and which does not necessarily have a causal relationship with the IP. An AE can be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of an IP. A serious adverse event (SAE) is an AE occurring during any study phase, that fulfils one or more of the following criteria: * Results in death; * Is immediately life-threatening; * Requires in-patient hospitalisation or prolongation of existing hospitalisation; * Results in persistent or significant disability or incapacity; * Is a congenital abnormality or birth defect; * Is an important medical event that may jeopardise the patient or may require medical treatment to prevent one of the outcomes listed above.
Time frame: From Day 1 of treatment up to the end of the follow-up period (Week 17)
Number of Patients Who Experienced Clinically Important Abnormalities in Clinical Laboratory Parameters
The number of patients who experienced clinically important abnormalities in clinical laboratory assessments as assessed by the Investigator are presented. Clinically important abnormalities in clinical laboratory parameters were reported as AEs. Clinical laboratory assessments included clinical chemistry, haematology and urinalysis performed at the central laboratory.
Time frame: From Day 1 of treatment up to the end of the follow-up period (Week 17)
Number of Patients Who Experienced Clinically Important Abnormalities in Vital Signs Measurements
The number of patients who experienced clinically important abnormalities in vital signs assessments as assessed by the Investigator are presented. Clinically important abnormalities in vital signs measurements were reported as AEs. Vital signs assessments included weight, pulse, and systolic and diastolic blood pressure measurements.
Time frame: From Day 1 of treatment up to the end of the follow-up period (Week 17)
Number of Patients Who Experienced Clinically Significant Changes in Electrocardiogram (ECG) Measurements
The number of patients who experienced clinically significant changes in ECG measurements as assessed by the Investigator are presented. Clinically important abnormalities in ECG measurements were reported as AEs. 12-lead ECGs were obtained using a digital ECG machine that automatically calculates the heart rate and measures PR, QRS, and QT (using QT interval corrected by Fredericia's algorithm) intervals.
Time frame: From Day 1 of treatment up to the end of the follow-up period (Week 17)
Number of Patients Who Experienced Low and High S-K Levels
The S-K levels used for this analysis were based on the measurements obtained by the central laboratory. Patients with S-K levels \< 3.5 mmol/L were considered to have low S-K levels. Patients with S-K levels \> 5.0 mmol/L were considered to have high S-K levels.
Time frame: From Day 1 of treatment up to the end of the follow-up period (Week 17)
Number of Events of Low and High S-K Levels
The S-K levels used for this analysis were based on the measurements obtained by the central laboratory. Patients with S-K levels \< 3.5 mmol/L were considered to have had an event of low S-K levels. Patients with S-K levels \> 5.0 mmol/L were considered to have had an event of high S-K levels.
Time frame: From Day 1 of treatment up to the end of the follow-up period (Week 17)
This study was performed at 64 sites in 9 countries (Brazil, Bulgaria, Canada, Hungary, Poland, Romania, Russia, Slovakia, and the United States of America) between 26 June 2018 and 22 May 2020.
| Milestone | Sodium Zirconium Cyclosilicate | Placebo |
|---|---|---|
| Started | 92 | 90 |
| Received treatment | 91 | 90 |
| Completed | 90 | 86 |
| Not completed | 2 | 4 |
| Withdrew: Other | 1 | 1 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Withdrawal by patient | 0 | 2 |
RAASi treatment categories: * No, or less than target dose, angiotensin converting enzyme inhibitors (ACEi)/ angiotensin receptor blockers (ARB)/ angiotensin receptor/ neprolysin inhibitors (ARNI) and no mineralocorticoid receptor antagonist (MRA); * ACEi/ARB/ARNI at target dose and no MRA; * MRA at less than target dose; * MRA at target dose. Missing values at 3 months were imputed using a multiple imputation approach with 10000 imputations. The imputation model included RAASi category at 3 months as the outcome variable and the following covariates: RAASi category, local lab-K, eGFR and systolic blood pressure measured at the last visit before the 3 months (starting with the randomisation visit) when all the covariates' data were available.
| Percentage of Patients | Sodium Zirconium Cyclosilicate | Placebo |
|---|---|---|
| No, or less than target dose ACEi/ARB/ARNI, no MRA | 14.7 | 13.5 |
| ACEi/ARB/ARNI at target dose and no MRA | 14.7 | 15.1 |
| MRA at less than target dose | 14.2 | 24.5 |
| MRA at target dose | 56.4 | 47.0 |
An AE is the development of any untoward medical occurrence in a patient or clinical study patient administered an investigational product (IP) and which does not necessarily have a causal relationship with the IP. An AE can be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of an IP. A serious adverse event (SAE) is an AE occurring during any study phase, that fulfils one or more of the following criteria: * Results in death; * Is immediately life-threatening; * Requires in-patient hospitalisation or prolongation of existing hospitalisation; * Results in persistent or significant disability or incapacity; * Is a congenital abnormality or birth defect; * Is an important medical event that may jeopardise the patient or may require medical treatment to prevent one of the outcomes listed above.
| Participants | Sodium Zirconium Cyclosilicate | Placebo |
|---|---|---|
| Any SAE | 14 | 10 |
| Any AE leading to discontinuation of IP | 5 | 2 |
| Any AE | 43 | 47 |
The number of patients who experienced clinically important abnormalities in clinical laboratory assessments as assessed by the Investigator are presented. Clinically important abnormalities in clinical laboratory parameters were reported as AEs. Clinical laboratory assessments included clinical chemistry, haematology and urinalysis performed at the central laboratory.
| Participants | Sodium Zirconium Cyclosilicate | Placebo |
|---|---|---|
| Anaemia | 1 | 1 |
| Iron deficiency anaemia | 1 | 0 |
| Hypoglycaemia | 1 | 1 |
| Hypertriglyceridaemia | 0 | 1 |
| Hyponatraemia | 0 | 1 |
The number of patients who experienced clinically important abnormalities in vital signs assessments as assessed by the Investigator are presented. Clinically important abnormalities in vital signs measurements were reported as AEs. Vital signs assessments included weight, pulse, and systolic and diastolic blood pressure measurements.
| Participants | Sodium Zirconium Cyclosilicate | Placebo |
|---|---|---|
| Hypotension | 4 | 1 |
| Hypertension | 2 | 0 |
| Hypertensive crisis | 1 | 1 |
| Blood pressure inadequately controlled | 0 | 1 |
The number of patients who experienced clinically significant changes in ECG measurements as assessed by the Investigator are presented. Clinically important abnormalities in ECG measurements were reported as AEs. 12-lead ECGs were obtained using a digital ECG machine that automatically calculates the heart rate and measures PR, QRS, and QT (using QT interval corrected by Fredericia's algorithm) intervals.
| Participants | Sodium Zirconium Cyclosilicate | Placebo |
|---|---|---|
| Number of Patients Who Experienced Clinically Significant Changes in Electrocardiogram (ECG) Measurements | 0 | 0 |
The S-K levels used for this analysis were based on the measurements obtained by the central laboratory. Patients with S-K levels \< 3.5 mmol/L were considered to have low S-K levels. Patients with S-K levels \> 5.0 mmol/L were considered to have high S-K levels.
| Participants | Sodium Zirconium Cyclosilicate | Placebo |
|---|---|---|
| S-K < 3.0 mmol/L | 0 | 0 |
| S-K < 3.5 mmol/L | 7 | 0 |
| S-K > 5.5 mmol/L | 23 | 32 |
| S-K > 6.0 mmol/L | 3 | 4 |
The S-K levels used for this analysis were based on the measurements obtained by the central laboratory. Patients with S-K levels \< 3.5 mmol/L were considered to have had an event of low S-K levels. Patients with S-K levels \> 5.0 mmol/L were considered to have had an event of high S-K levels.
| Events | Sodium Zirconium Cyclosilicate | Placebo |
|---|---|---|
| S-K < 3.0 mmol/L | 0 | 0 |
| S-K < 3.5 mmol/L | 12 | 0 |
| S-K > 5.5 mmol/L | 37 | 59 |
| S-K > 6.0 mmol/L | 3 | 4 |
Collected over From Day 1 of treatment up to the end of the follow-up period (Week 17). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sodium Zirconium Cyclosilicate | 1/91 (1.1%) | 14/91 (15.4%) | 16/91 (17.6%) |
| Placebo | 1/90 (1.1%) | 10/90 (11.1%) | 7/90 (7.8%) |
| Event | Sodium Zirconium Cyclosilicate | Placebo |
|---|---|---|
| Cardiac failure chronicCardiac disorders | 2/91 | 2/90 |
| Acute myocardial infarctionCardiac disorders | 2/91 | 1/90 |
| Cardiac failure acuteCardiac disorders | 2/91 | 1/90 |
| BronchitisInfections and infestations | 0/91 | 1/90 |
| OsteomyelitisInfections and infestations | 0/91 | 1/90 |
| PneumoniaInfections and infestations | 1/91 | 1/90 |
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 0/91 | 1/90 |
| HyponatraemiaMetabolism and nutrition disorders | 0/91 | 1/90 |
| SyncopeNervous system disorders | 0/91 | 1/90 |
| Angina unstableCardiac disorders | 0/91 | 1/90 |
| Event | Sodium Zirconium Cyclosilicate | Placebo |
|---|---|---|
| Cardiac failure chronicCardiac disorders | 7/91 | 2/90 |
| Viral upper respiratory tract infectionInfections and infestations | 6/91 | 3/90 |
| Chronic kidney diseaseRenal and urinary disorders | 5/91 | 3/90 |
| Age, Continuous(years) | Sodium Zirconium Cyclosilicate | Placebo | Total |
|---|---|---|---|
| Mean | 72.9 ± 8.8 | 71.0 ± 8.1 | 71.9 ± 8.5 |
| Age, Customized(Participants) | Sodium Zirconium Cyclosilicate | Placebo | Total |
|---|---|---|---|
| ≤ 17 years | 0 | 0 | 0 |
| 18 - 64 years | 17 | 16 | 33 |
| 65 - 84 years | 65 | 69 | 134 |
| ≥ 85 years | 10 | 5 | 15 |
| Sex: Female, Male(Participants) | Sodium Zirconium Cyclosilicate | Placebo | Total |
|---|---|---|---|
| Female | 41 | 33 | 74 |
| Male | 51 | 57 | 108 |
| Ethnicity (NIH/OMB)(Participants) | Sodium Zirconium Cyclosilicate | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 15 | 14 | 29 |
| Not Hispanic or Latino | 77 | 76 | 153 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Sodium Zirconium Cyclosilicate | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 |
| White | 90 | 89 | 179 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| S-K Concentration(Participants) | Sodium Zirconium Cyclosilicate | Placebo | Total |
|---|---|---|---|
| ≤ 5.0 mmol/L | 65 | 67 | 132 |
| > 5.0 mmol/L | 27 | 23 | 50 |
| New York Heart Association (NYHA) Functional Classification(Participants) | Sodium Zirconium Cyclosilicate | Placebo | Total |
|---|---|---|---|
| Class I | 0 | 0 | 0 |
| Class II | 61 | 57 | 118 |
| Class III | 31 | 33 | 64 |
| Class IV | 0 | 0 | 0 |
| Left Ventricular Ejection Fraction (LVEF)(LVEF Percentage) | Sodium Zirconium Cyclosilicate | Placebo | Total |
|---|---|---|---|
| Mean | 33.8 ± 5.8 | 33.9 ± 6.1 | 33.8 ± 6.0 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jun 2018 to primary completion in May 2020, 22 months.
Results were first posted in Jun 2021, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sodium zirconium cyclosilicate